



सीएसआईआर-कोशिकीय एवं आणविक जीवविज्ञान केन्द्र
CSIR-CENTRE FOR CELLULAR & MOLECULAR BIOLOGY

(वैज्ञानिक तथा औद्योगिक अनुसंधान परिषद्)

(COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH)

उप्पल रोड, हैदराबाद/Uppal Road, Hyderabad – 500 007 (तेलंगाना/TELANGANA) भारत/India

File Ref: BDG/TS/1785/2020-21/002

Date: 27.01.2021

TENDER ID: 2021 CSIR 66807 1

SUB: Amendment to original Tendered Technical Specifications for procurement of Technical Services (Outsourcing of DNA Sequencing Facility at CCMB to provide onsite Sequencing Services for a period of 3 years – Reg.

With reference to **Pre-Bid Conference (PBC)** held on **20.01.2021** to finalize the tendered specifications, all bidders are requested to take a **NOTE** of the **CHANGES** in the tendered specifications at **REVISED ANNEXURE-1** placed below. **Accordingly, tendered specifications of Technical Services (Outsourcing of DNA Sequencing Facility at CCMB to provide onsite Sequencing Services for a period of 3 years mentioned under Annexure 1 is completely substituted by REVISED ANNEXURE 1 placed below (Page 2) and bidders in their own interest are advised to carefully go through changes before submitting their e-bid.**

There is **no change** in **other Terms and Conditions** of the original **Tender Document**.

Bidders are advised to submit their **e-bids** as per **original schedule** given in the **Tender Document** on the subject which is also **reproduced** below for information.

| | |
|---|---------------------------------------|
| Bid submission Start Date & Time | 27.01.2021 (18.30 hrs onwards) |
| Bid submission End Date & Time | 08.02.2021 (Up to 13.00 hrs) |
| Date & Time for opening of Bids | 09.02.2021 (From 14.30 hrs) |

Sd/-
[Dharmendra Kumar]
Stores & Purchase Officer

REVISED SPECIFICATIONS FOR THE TENDER 'OUTSOURCING OF DNA SEQUENCING FACILITY AT CCMB TO PROVIDE ONSITE-SEQUENCING SERVICES FOR A PERIOD OF THREE YEARS'

1. Objective

Over the years, CCMB has established a well-equipped centralized DNA sequencing facility. The objective is to outsource the management and running operations of this facility through a third party (private) operator to provide efficient and cost-effective quality DNA Sequencing and Genotyping services within a short turnaround time so that the research community in CCMB can devote their time on other core activities.

2. Broad Description of CCMB's Service Requirements

CCMB investigators / researchers will provide sample in the mutually agreed quantities and concentration. The selected vendor will be responsible for:

Full DNA sequencing services to be provided as follows:

- a) Check the DNA quality
- b) Setup the sequencing reaction
- c) Cleanup the extended product.
- d) Operate and run the instruments for data collection
- e) To generate a minimum read length of 600 bases per sequencing reaction
- f) To deliver the results directly to investigators on to a designated computer in standard formats (chromatogram, Fasta).
- g) Built in quality control system to be incorporated into the sequencing pipeline and to indicate how this will be implemented.
- h) To assist users in data analysis and troubleshooting.
- i) Genotyping services also to be provided as per the requirement of users.

3. The Selected Eligible Vendor Will Be Provided Following Facilities in CCMB

DNA sequencing facility having four DNA sequencers, procured from M/s Applied Biosystems, and the details of the DNA Sequencers are as follows:

- a. Model ABI 3730s (03 Nos.):
 - 48 capillary array-based Sequencer installed in 2004 Serial no 16108-011
 - 48 capillary array-based Sequencer installed in 2005 Serial no 17119-006
 - 48 capillary array-based Sequencer installed in 2007 Serial no 18130-002
- b. Model ABI 3730XL (1 no) Serial no 19134-002: 96 capillary array-based Sequencer installed in 2007.
- c. Model ABI 3130XL (1 no) Serial no 19237-020: 16 capillary array-based Sequencer installed in 2007.
- d. Sequencing analysis, GeneMapper and Seq Scape software (single user licenses only) are available for downstream data analysis.
- e. Central air-conditioning in the Sequencing facility, uninterrupted power supply through a central UPS system, Mill Q water, networking and telephone will be provided.
- f. Sitting place/desk for 2 to 3 operators will be provided in the facility.
- g. Other infrastructural facilities like internet connectivity, simple IT and instrumentation troubleshooting help (occasionally) and waste disposal services.

RESPONSIBILITIES OF CCMB

- (i) CCMB shall make available the 'FACILITY' to the VENDOR for use upon signing of the Agreement in a manner mutually decided.
- (ii) CCMB shall give access to the said premises to the Vendor employees only for purpose of convenience of the work as per CCMB norms.
- (iii) CCMB during the period of use of the FACILITY retains the option to withdraw the permission of use of FACILITY by the VENDOR in case CCMB requires the use of the FACILITY for its own purpose/ and or for national/strategic use. CCMB and the VENDOR shall mutually discuss exercising of such option and shall settle the terms thereof mutually.
- (iv) CCMB shall administer/ monitor the functioning of the permission of the use of the FACILITY by the VENDOR.

RESPONSIBILITIES OF VENDOR

- (i) The VENDOR shall provide to the CCMB the details of the purposes for which FACILITY is to be used, working plan with program of activities, timings of actual work, day to day related issues, etc. upon signing of the agreement.
- (ii) The VENDOR shall be responsible for all legal/operational matters/meeting of statutory requirements if any pertaining to the use of the FACILITY. CCMB if need be shall provide assistance/advice in this regard to the VENDOR on terms mutually agreed to.
- (iii) The personnel of the VENDOR deployed at the CCMB in connection with the use of FACILITY shall remain the responsibility of the VENDOR and shall have no claim of employment on CCMB. These personnel shall be subject to administrative discipline of the CCMB.
- (iv) The VENDOR shall allow access to the authorized representative of CCMB at mutually agreed time to inspect/visit/check the FACILITY as measure of administrative/ management functions.
- (v) The VENDOR shall not, at any time assign, mortgage, sub-lease/ sub-contract/ hire out the FACILITY.
- (vi) he VENDOR acknowledges the absolute ownership of CCMB on the FACILITY and shall not challenge in any way the legality, validity or enforceability of the permission granted and ownership rights of CCMB.
- (vii) The VENDOR shall report immediately to the CCMB, upon any accident/ damage/ loss/ theft/ misuse occurred during the usage/ utilization of the FACILITY with complete information and extend full coordination to the CCMB and abide by the decisions of the Director of the CCMB for remedial actions.
- (viii) The VENDOR shall be liable to CCMB for any loss/damage to the property and personnel of CCMB arising out of or subsequent to use of the FACILITY if the same has arisen solely out of use of FACILITY. The nature of loss/damage, extent of liability and monetary claim in this respect shall be decided by the Director of the CCMB whose decision shall be final and binding on the VENDOR.

17. Workload of CCMB: Minimum quantity of samples (as plasmids & PCR products) is approximately **12000 numbers** per quarter on an average.

18. To be provided by the vendor:

- (i) Vendor is solely responsible for the following and commitment to this effect to be made in the offer.
- (ii) Procurement of consumables & reagents (of quality and make as specified by CCMB) required for running the facility.
- (iii) Procurement of other small equipment needed for performing DNA sequencing, such as PCR machines, centrifuges, freezers, gel apparatus, PC, etc. required for the facility.

(iv) Procurement of spares and consumable for the repairs & maintenance. To get into AMC / CMC contract with the competent service providers for procurement of spares and also for the repairs and maintenance.

(v) Vendors may specify their own formats and labelling protocols in consultation with the CCMB user community for requisition of various services and correct identification and tracking of samples.

19. SUGGESTED MODEL FOR FINANCIAL COMPARISON (as per annexure 2 attached)

(i) Financial comparison of eligible bidders will be done on the basis of 80% sequencing samples and 20% other samples.

(ii) Tentative minimum volume of samples (as plasmids & PCR products) is **approximately 12000** samples/quarter on an average.

(iii) The firm will have to specify in percentage terms for the following:

(a) Percentage of quoted prices per sample that will be given as **extra discount (> 7.5%)** if the sample quantity of CCMB work exceeds **1200 samples** or more per quarter.

(b) Weightage will be given to quantum of discount greater than **7.5%** (graded weightage based on discount offered beyond **7.5%**, refer to Annexure 2 for details), if the sample quantity of CCMB work exceeds 10% (i.e. **1200 samples** or more per quarter).

(c) A revenue sharing of 30% for a quarterly turnover beyond 5.0 lakhs and 15% for a quarterly turnover less than 5.0 lakhs.

Important Conditions:

(i) To clearly mention the DNA template type & quality requirements, Amount of template/reaction and volume requirements, primer concentration & volume requirements and any other details needed.

(ii) To indicate the years of experience (minimum two years experience in the last five years required) gained in operating and running such facilities to third party clients giving details of where such facilities are being offered in and outside India and to also provide contact details

(iii) To indicate what will be the system for users to submit sequencing requests online.

27) Data to be archived for at least six months on the vendor archives, which can be recovered upon request by the user.

(iv) Maximum turnaround time of samples submitted for sequencing/genotyping should be 3 working days

(v) To indicate the remedial action that would be taken in case of run / reaction failures.

30) Failed reactions should not be charged once sample is accepted as per point number (24)

(vi) The prices offered should be valid for a period of three years.

(vii) Backup services in case of breakdowns etc. to be indicated. In case of loss of data due to fault of service provider, the service provider should ensure that entire work over the last six months is done at their cost or reimburse to CCMB the expenditure incurred for getting the same done at third party.

(viii) Approved ISO certifications to be attached.

(ix) After the contract expires the Instrument should be handed over in good working condition i.e. it should be handed over in the same condition as it was before contract begins and should be committed in the offer.

(x) GST and other charges to be indicated separately in the offer.

(xi) Vendor should give a commitment that in case of non-availability of service for a maximum of one week, it would be the service provider's responsibility to get the CCMB samples analyzed

elsewhere at their cost. However, the charges and turnaround time to CCMB will remain as per rates and turnaround time agreed by CCMB (as per purchase order).

Please respond to each and every point in the proposal. Decision will be taken based on your response to all the points mentioned.

REVISED FORM-09 (MANDATORY)

| Activity Description | | Weightage | | | | | | | | | | | | |
|---|---|------------|-----------|------|---|---------|---|--------|---|--------|---|------|---|---|
| I. Sequencing Services | | | | | | | | | | | | | | |
| a) Template (Plasmid/PCR product) | a. Without purification | 20 | | | | | | | | | | | | |
| | b. With purification | 60 | | | | | | | | | | | | |
| b) Only Running the sample (Sample ready to load will be provided by the user. Sequence length / failure conditions will not be implemented in such case) | | 1 | | | | | | | | | | | | |
| c) Primer Walking (per kb) (Include generating DNA sequence data from the genomic DNA flanking a known sequenced region provided by the user. It also includes primer design synthesis and sequencing. Turnaround time is 5 working days) | | 0 | | | | | | | | | | | | |
| II. Genotyping – Microsatellite / SNP analysis | | | | | | | | | | | | | | |
| a) Allelic data per sample (includes only running the sample) | a. Without size marker | 10 | | | | | | | | | | | | |
| | b. Without Primer | 2 | | | | | | | | | | | | |
| b) Allelic Data per sample (include PCR amplification and running the sample with appropriate size marker using the template provided by the user) | a. Without Primer | 1 | | | | | | | | | | | | |
| | b. With Primer | 1 | | | | | | | | | | | | |
| III) Weightage of discounts > 7.5% | <table border="1"> <thead> <tr> <th>Percentage</th> <th>Weightage</th> </tr> </thead> <tbody> <tr> <td>7.5%</td> <td align="right">1</td> </tr> <tr> <td>7.5-10%</td> <td align="right">2</td> </tr> <tr> <td>10-12%</td> <td align="right">3</td> </tr> <tr> <td>12-14%</td> <td align="right">4</td> </tr> <tr> <td>>14%</td> <td align="right">5</td> </tr> </tbody> </table> | Percentage | Weightage | 7.5% | 1 | 7.5-10% | 2 | 10-12% | 3 | 12-14% | 4 | >14% | 5 | 5 |
| Percentage | Weightage | | | | | | | | | | | | | |
| 7.5% | 1 | | | | | | | | | | | | | |
| 7.5-10% | 2 | | | | | | | | | | | | | |
| 10-12% | 3 | | | | | | | | | | | | | |
| 12-14% | 4 | | | | | | | | | | | | | |
| >14% | 5 | | | | | | | | | | | | | |
| Total Marks (based on weight assigned out of 100) | | 100 | | | | | | | | | | | | |

**(TO BE UPLOADED ALONG WITH BOQ AS PART OF PRICE SCHEDULE AS PRICE BID)
FINAL SELECTION OF L1 VENDOR WILL BE DONE ON THE BASIS OF THIS REVISED FORM-09 DOCUMENT ONLY**

Minutes of the Pre-Bid meeting held on 20th Jan 2021 (from 11.00am onwards - Director Committee Room) for **"Outsourcing of DNA Sequencing facility at CCMB" (File reference BDG/TS/1785/20-21/2)**

CCMB representatives / officials present during the presentation:

1. Dr.Tushar Vaidya
2. Dr. G.R. Chandak
3. Dr. Archana B Siva
4. Dr. Ajay gaur
5. Dr. Karthik Bhardwaj
6. Ms.Asha Ramesh
7. Mr.Dharmendra Kumar,Special Invitee

Representatives of the following firms attended the meeting and also given technical presentation:

1. M/s Eurofins Genomics India Pvt.Ltd,Banglore
2. M/s .Bioserve Biotechnologies (India) Pvt.Ltd

At the outset Ms. Asha Ramesh welcomed representatives of participating firms. The representatives of different firms introduced themselves and after that a general discussion on the technical details, Specifications and Service Criteria, Price Schedule and Qualification Requirements (chapters 4-6 in the tender document) took place for any clarifications, suggested changes, etc.

The following points were raised by the participating bidders seeking changes:


- Point 6: Workload of CCMB: Bioserve suggested a change from CCMB minimum commitment from 8000 to 16000; while Eurofins suggested a change from 8000 to 20000.
- Point 8 (iii) a: Tender document says that percentage of the quoted prices per sample that will be given as extra discount (>5%) would be offered if the sample quantity of CCMB workload exceeds 10% [i.e. 800 samples or more per yearly quarter]. It was agreed upon that the discount shall be offered for a minimum on 8000 samples per yearly quarter.
- Point 8 (iii) b: Tender document says that weightage will be given to quantum of discount greater than 5% (graded weightage based on discount offered beyond 5%) if sample quantity of CCMB workload exceeds 10% (i.e. 800 samples or more per yearly quarter). This would now read as "weightage will be given to quantum of discount greater than 5% (graded weightage based on discount offered beyond 5%) if sample quantity of CCMB workload exceeds minimum quantity of 8000 samples per yearly quarter".
- Point 8 (iii) c: It was suggested by both vendors that the revenue sharing to be kept at the existing rate of 15% of the turnover generated by the service provider for carrying out outside samples using CCMB facility, for turnover of 8.0 lakhs per yearly quarter and 30% for turnover above 8.0 lakhs per yearly quarter (the rates in the tender document is for a turnover of 5.0 lakhs or above per yearly quarter).

The Points raised by the participating bidders will be discussed further by the technical committee and requested change, if agreed, will be uploaded in CPPP and CCMB website in due course.



Name of Participating firm

Signature


1. M/s Eurofins Genomics India Pvt.Ltd



(Pritam Sarkhel)


2. M/s .Bioserve Biotechnologies (India) Pvt.Ltd
0.


(Dr. Jasna) 
(Mr. Sunil)


CCMB team


(Dr. Tushar Vaidya)


(Dr. G.R. Chandak)


(Dr. Archana B Siva)


(Dr. Ajay gaur)


(Dr. Karthik Bhardwaj)


(Ms. Asha Ramesh)